Multi-agent AI delivers reliable and scalable insights for single-cell omics

What It Covers

Parashar Dhapola, CEO of NIGEN Analytics, explains how multi-agent AI systems address the core bottleneck in single-cell omics: cell type annotation. He covers where AI genuinely delivers in biopharma, why cherry-picking poses greater risk than hallucination, and how CytType compresses weeks of iterative analysis into minutes.

Key Questions Answered

• •Single-cell analytics pipeline structure: Divide single-cell workflows into three distinct phases — primary (raw sequencing to structured gene-cell matrix), secondary (clustering, batch correction via tools like Scanpy or Seurat), and tertiary (biological interpretation and annotation). Pharma now considers the first two phases stable enough for regulatory submissions; the tertiary phase remains the primary bottleneck and efficiency target.
• •Cherry-picking risk over hallucination: When deploying LLMs for cell annotation, the greater danger is not fabricated outputs but selective gene focus — an LLM assessing 10 genes while ignoring 7. Guard against this by architecting fan-out parallel analysis across thousands of genes simultaneously, then pruning results back, trading speed for comprehensive coverage measured in minutes rather than weeks.
• •Agentic annotation with evidence trails: CytType uses specialized LLM agents that cross-reference marker genes against literature, validate conclusions, and log every rejected hypothesis into structured data models. This produces traceable HTML reports with a chat interface, allowing wet-lab biologists to interrogate annotation reasoning directly without routing every question back through bioinformaticians.
• •Annotation resolution determines downstream discovery value: Coarse cell-type labels degrade differential expression analysis, pathway analysis, and target prioritization built on top of them. Resolving subtypes — distinguishing pro-inflammatory from suppressive macrophages, or active from exhausted T cells — directly determines whether a patient qualifies for cell therapy and enables reproducible biomarker validation across cohorts and time points.
• •Virtual cell models are 4–5 years from deployment: Foundation models like scGPT apply transformer architectures to single-cell data but currently underperform classical machine learning on benchmarks. Federated pharma infrastructure initiatives, such as Eli Lilly's TuneLab with NVIDIA, are accumulating the large-scale perturbation datasets needed for emergent reasoning capabilities, but practical deployment systems remain at least four to five years away.